Charles T. Robbins

This paper introduces a method using real-time luminescence to estimate drug response in cell lines, avoiding the need for cell counting and fluorescent labeling.

This study disentangles genetic, epigenetic, and stochastic factors contributing to drug-response variability in an in vitro tumor heterogeneity model using PC9 cell lines.

The paper shows that increased antioxidant capacity in BRAF-mutated melanoma cells reduces sensitivity to BRAF inhibitors and suggests targeting redox pathways could improve treatment outcomes.